Exploring NCATS in-house biomedical data for evidence-based drug repurposing.
Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical indication. Even though many repurposed drugs have been found serendipitously in the past, the increasing availability of large volumes of biomedical data h...
Main Authors: | Fang Liu, Andrew Patt, Chloe Chen, Ruili Huang, Yanji Xu, Ewy A Mathé, Qian Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0289518&type=printable |
Similar Items
-
Exploring NCATS in-house biomedical data for evidence-based drug repurposing
by: Fang Liu, et al.
Published: (2024-01-01) -
Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma
by: Erin McGowan, et al.
Published: (2023-09-01) -
DEIA is essential to advance the goals of translational science: Perspectives from NCATS
by: Shadab F. Hussain, et al.
Published: (2023-01-01) -
Financing translation: Analysis of the NCATS rare-diseases portfolio
by: Fagnan, David E., et al.
Published: (2015) -
QuaNCAT: Quantitating proteome dynamics in primary cells
by: Howden, A, et al.
Published: (2013)